Skip to content
OpenCapital
Get started

United Therapeutics UTHR Orenitram — Total revenues

Other product segments

Tyvaso DPI
$330.3M+9.2%
Nebulized Tyvaso
$127.2M-22.3%
Remodulin
$126.6M-8.4%
Unituxin
$53.6M-7.9%
Adcirca
$2.9M-51.7%

Similar metrics at other companies

Bristol-Myers Squibb logo
BMYOrencia — Total Revenues
$818M+6.2%
Amgen logo
AMGNOtezla — Total revenues
$431M-1.4%
Supernus Pharmaceuticals logo
SUPNOxtellar XR — Total revenues
$7.42M-27.2%
Tarsus Pharmaceuticals, Inc. logo
TARSProduct sales, net — Total revenues
$145.39M+85.6%
Organon logo
OGNOntruzant — Revenue
$5M-72.2%
PTH
PTHSNet product revenues — Total Revenue
$10.67M—

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M—
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity0×—
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's orenitram — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's orenitram — total revenues?
United Therapeutics (UTHR) reported orenitram — total revenues of $135.6M in Q1 2026.
How has United Therapeutics's orenitram — total revenues changed year-over-year?
United Therapeutics's orenitram — total revenues increased by 12.3% year-over-year, from $120.7M to $135.6M.
What is the long-term trend for United Therapeutics's orenitram — total revenues?
Over 4 years (2021 to 2025), United Therapeutics's orenitram — total revenues has grown at a 12.9% compound annual growth rate (CAGR), from $306.1M to $496.9M.
What does orenitram — total revenues mean?
Represents the total gross sales generated from the commercial sale of a specific pharmaceutical product used to treat pulmonary arterial hypertension. This metric captures the top-line performance of the product line before the deduction of any cost of goods sold. It serves as a primary indicator of market adoption and demand for this specific therapeutic intervention.